Abstract

Introduction. Von Hippel-Lindau (VHL) syndrome is a pathological condition that causes various clinical symptoms and is difficult to diagnose. The most common pathological lesions are hemangioblastomas of the central nervous system, retinal angiomas, renal clear cell carcinomas, and pheochromocytomas. Case Report. A 23-year-old female had a syncope episode in 2008. Magnetic resonance imaging (MRI) revealed a right temporal hemangioblastoma, which was treated surgically. Genetic screening identified a VHL gene mutation, and computed tomography (CT) revealed a left adrenal mass. Since it was unclear whether the mass was a pheochromocytoma, or another benign or malignant tumors, laparoscopic adrenalectomy was performed. A month after surgery, the patient complained of general fatigue, poor concentration, loss of appetite, and insomnia. After careful clinical investigation, the patient was referred to a psychiatrist due to suspected depression, which was confirmed. Conclusions. VHL genetic screening should be performed in cases of hemangioblastoma. In VHL syndrome cases, pheochromocytoma cannot always be diagnosed by biochemical catecholamine analyses; therefore, CT or MRI scanning of the abdomen must be performed. Due to the long treatment period, some patients may develop episodes of depression, which can simulate VHL syndrome.

Highlights

  • Von Hippel-Lindau (VHL) syndrome is a pathological condition that causes various clinical symptoms and is difficult to diagnose

  • Type 2c is characterized by a high risk of pheochromocytoma, whereas type 3 is characterized by a risk of Chuvash polycythemia [2]

  • The VHL gene is located on chromosome 3p25, consists of three exons [4], and produces at least two isotypes of pVHL. pVHL mainly acts by directly regulating the levels of hypoxia-inducible transcription factor types 1 and 2 (HIF1 and HIF2), which play important roles in the cellular response to oxygen deficiency

Read more

Summary

Introduction

Von Hippel-Lindau (VHL) syndrome is a rare hereditary cancer characterized by benign or malignant tumors. The most common VHL syndrome-associated tumors are hemangioblastomas of the central nervous system, pheochromocytomas, retinal angiomas, neuroendocrine tumors, clear cell renal carcinomas, and middle ear tumors that affect the endolymphatic sac [1]. Type 1 is characterized by a high risk of renal cell carcinoma and a low risk of pheochromocytoma. Types 2a and 2b are characterized by a high risk of both renal cell carcinoma and pheochromocytoma. The VHL gene is located on chromosome 3p25, consists of three exons [4], and produces at least two isotypes of pVHL (a tumor suppressor protein). When pVHL is not produced due to VHL gene mutations (mostly deletions), HIF is not blocked; this promotes angioneogenesis and uncontrolled cell proliferation. PVHL mutations seriously increase the risk of tumor growth in target organs

Case Presentation
Findings
Discussion
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call